Brian Reed: Hey. Good to be back.
Eliza Ward: Yeah, good — did you catch the Reuters thing this morning?
Brian Reed: The FDA story. Yeah, I did. And I'm still kind of — let me see — I don't think I've fully processed it yet. Reuters, November 12th, six sources, internal documents: the Commissioner's National Priority Voucher program is effectively dead.
Eliza Ward: The CNPV. Gone quiet.
Brian Reed: Gone quiet is a generous way to put it. The executive council that was supposed to oversee these reviews — just stopped meeting. No announcement, no formal closure, no vote. Marty Makary leaves, and the whole thing kind of... evaporates.
Eliza Ward: Wait — eleven approvals. That's what gets me. The pilot ran from June 2025, nine programs got the initial vouchers, eleven drugs actually cleared in that window. And then — council goes dormant. No new vouchers issued.
Brian Reed: Eleven approvals and then a switch gets flipped. That's the part I keep returning to — was this a program, or was this one person's project?
Eliza Ward: And the FDA is still — publicly — saying applications are open. But sources told Reuters they won't advance. That gap right there is the story.
Brian Reed: And that gap — the sign is still up, the desk still looks open — but walk up to it and nothing moves. That's the actual new information, right? Not that the program slowed down. That the FDA is maintaining two completely different positions at the same time.
Eliza Ward: Fast-pass lane at the airport. Staff walked away. Sign's still lit.
Brian Reed: Exactly that. And Pink Sheet confirmed it independently — same date, November 12th — FDA will honor existing awards, but the pilot is winding down. So we've got Reuters, Pink Sheet, Fierce Pharma, all with slightly different words: 'shelved,' 'winding down,' 'paused.' That variance alone tells you something about how opaque this actually is.
Eliza Ward: Wait — the Rasonque detail throws me off.
Brian Reed: Yeah, so — hang on — Revolution Medicines' pancreatic cancer drug. CNPV recipient. And it goes through the FDA Oncology Center of Excellence, under the existing real-time oncology review framework. No council involvement documented. At all.
Eliza Ward: Right, and — pancreatic cancer. That should be the exact disease the CNPV was designed to prioritize. If Rasonque needed the council and didn't use it, that's one thing. But if the Oncology Center of Excellence just... handled it anyway, then either the council had already stopped functioning before anyone admitted it, or it was never actually necessary to produce the speed.
Brian Reed: So the council was maybe — I mean, let me see if I'm reading this right — it was possibly decorative by the time Rasonque went through?
Eliza Ward: That's the inference. The confirmed fact is: no CNPV council involvement documented in the review record. The inference — which I want to hold loosely — is that the council had already become a fiction before anyone said so publicly. We don't have hard causation. Reuters's sourcing is atmospheric on that part.
Brian Reed: So the question isn't just is the program dead — it's: was it already hollow when it looked alive? And nine companies got vouchers betting it wasn't.
Eliza Ward: And that's exactly the take I want to push on — because the story that's already circulating this morning is 'FDA politicized drug reviews.' And I'm not sure that's what we actually have.
Brian Reed: That's the one. Yeah. 'Political appointees on the council, therefore corrupt.' I keep seeing that framing and it's — I mean, let me think about this — it conflates two really different problems.
Eliza Ward: What's the distinction you're drawing?
Brian Reed: Political discretion as a design flaw versus political appointees actively overriding scientific staff. Those are not the same thing. The CNPV had no statutory foundation — Makary stood it up in June 2025 as a pilot, oversight vested in an internal executive council. Congress didn't create this. The Priority Review Voucher program from 2007, that's the congressionally-built infrastructure. The CNPV was just... layered on top of it, with no equivalent legislative authority. So when Makary leaves, there's nothing holding it. That's fragility, not necessarily corruption.
Eliza Ward: Right — but I don't want to let the structural argument clean up the selection criteria problem. Critics raised real concerns: unclear criteria for which drugs got vouchers, possible linkage between review speed and drug pricing agreements with the Trump administration. That's not proven, but it's not nothing.
Brian Reed: No, that's fair. Those are confirmed concerns — Reuters reported them. I just want to hold them separately from 'bad drugs got forced through.' Because Rasonque going through the Oncology Center of Excellence on the existing framework actually suggests the science wasn't bypassed. It was the council that was bypassed.
Eliza Ward: Which is a structural flaw, not a scientific one. Those are answerable with different fixes.
Brian Reed: Exactly — and the people getting hurt by that distinction are real. Picture a regulatory affairs director, November 13th, morning after Reuters publishes. She pulls up the FDA's public CNPV page — still says open. Her inbox has a note from their FDA contact: informally, it won't move. That's not a policy reversal she can point to. There's no document. No announcement. Nothing to show her board.
Eliza Ward: And the fallback options — that part gets complicated, actually. That comes next.
Brian Reed: And 'fallback options' is — that phrase is doing a lot of work right now for a lot of companies, because the gap isn't small. Priority review, the statutory pathway, that's a six-month target. The CNPV was promising one to two months. So a company that staffed a launch team, opened manufacturing lines, locked in supply contracts around a four-month total cycle — they're now looking at potentially tripling that timeline. No formal notice. No conversion process. Just... informally told it won't move.
Eliza Ward: And there's no formal process to escalate those stranded applications into the priority review queue. That's confirmed. No pipeline, no bridge.
Brian Reed: So what does a company actually do at that point?
Eliza Ward: Fast-track, breakthrough therapy designation, accelerated approval — those exist. But none of them replicate a one-to-two-month window. Breakthrough therapy gets you closer, more FDA interaction, real rolling review — but the target's still months, not weeks.
Brian Reed: The RBC analysts flagged COMP360 specifically — it holds breakthrough therapy designation already, so they said exposure to the CNPV wind-down is manageable. And I think that's probably right. But manageable is not equivalent. That's — I mean, that framing is doing some work there. A cushion is not a replacement for the runway you built your budget around.
Eliza Ward: Right — COMP360 has a lifeboat. Most of the nine don't have that same designation sitting there waiting.
Brian Reed: And the Rare Disease Framework Initiative — unveiled October 2026, which is recent — does that change anything here?
Eliza Ward: Genuinely don't know, and I want to be careful. It's real — active, FDA-launched, patient perspectives built in, aimed at fit-for-purpose rare disease development. But sources do not confirm it's a replacement for the CNPV. It hasn't addressed the structural flaws critics raised. It might be complementary, might be coincidental timing. We can't draw the line between them yet.
Brian Reed: So the thing to watch is whether the FDA formally routes any of those nine stranded programs into the Rare Disease Framework or into breakthrough designation — that's the signal. Not what anyone says the program means. What actually happens to those applications.
Eliza Ward: And that signal — whether applications move or sit — that's the only test that matters right now. Not announcements. Not the Rare Disease Framework language. What actually happens to those nine.
Brian Reed: Right — but the part that doesn't fit is the lesson question. Because you can get to one to two months, that's what eleven approvals in under eighteen months actually proves. The CNPV did that. It also proved that speed built entirely on one commissioner's informal council disappears the moment that commissioner does. So someone at the FDA, or someone in Congress, has to decide: do we want that speed locked into statute, or do we just keep reinventing the same fragile pilot every few years with a different person's name on it?
Eliza Ward: And we genuinely don't know the answer yet. That's — I mean, that's the actual open thread here. The statutory Priority Review Voucher program, Congress built that in 2007, it's durable, it's still running. But it was never designed to deliver one-to-two-month reviews at scale. Those are different tools.
Brian Reed: So what are you watching for? Not hoping for — actually watching.
Eliza Ward: Whether whatever comes next has a statutory foundation or another informal council. That's it. Not whether a replacement gets announced — announcements are easy. If the FDA or Congress moves toward codifying compressed review timelines with transparent criteria, that's a different story than a new pilot with a new commissioner's name on it. Same design flaw, new branding.